Burlingame, California, Dec 20, 2022 – Synlico Inc. (“Synlico”), a biotechnology company developing cutting-edge T cell therapies for the treatment of solid tumors, announced that it will attend the 2023 Biotech Showcase – Seed Showcase and present the revolutionary technology the company is developing to change the way of drug discovery and design.
Synlico combines the latest advancements in system biology, single-cell bioinformatics, and synthetic biology to create a computational platform to analyze the signaling pathways and gene regulatory networks of T cells at the single cell level. The platform is designed to harness the power of single-cell analysis to generate data-driven insights and iteratively improve drug designs by learning from the engineering process.
Synlico’s CEO, Dr. Jingwei Lu commented: “Synlico is on a vision to rewrite biology and medicine with data-driven computing. Our platform focuses on tackling the complexity and heterogeneity of the tumor microenvironment, one of the major challenges that hinder CAR-T cell therapy against the solid tumor. Our platform will enable us to engineer T cells that specifically target each patient’s unique needs.”
Details of the presentation are as follows:
Title: Data Driven Computational Interpretation of Medicine and Biology
Date and Time: January 11, 2023, 9:10 AM
Location: Hilton San Francisco Union Square, 333 O’Farrell Street, San Francisco, CA, USA